Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose

Summary by neurologylive.com
Roche has updated its phase 3 GENERATION HD2 trial to continue testing only the higher 100 mg dose of tominersen, following interim data favoring its potential clinical benefit in Huntington disease.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

neurologylive.comneurologylive.com

GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose

Roche has updated its phase 3 GENERATION HD2 trial to continue testing only the higher 100 mg dose of tominersen, following interim data favoring its potential clinical benefit in Huntington disease.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Thursday, April 24, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal